Trial Profile
A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of Once Daily Raltegravir (MK0518) Versus Twice Daily Raltegravir, Each in Combination With TRUVADA, in Treatment-Naïve HIV Infected Patients
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms QDMRK
- Sponsors Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 15 Jun 2019 This trial has been completed in France.
- 09 Sep 2014 Results of a racial subgroup analysis on the efficacy and safety of raltegravir presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 02 Mar 2011 Results presented at the 18th Conference on Retroviruses and Opportunistic Infections.